Please login to the form below

Not currently logged in


This page shows the latest biosimilar news and features for those working in and with pharma, biotech and healthcare.

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

Kadcyla’s resurgence has helped support Roche’s HER2 franchise as Herceptin – now off-patent – has started to feel the effects of biosimilar competition.

Latest news

More from news
Approximately 136 fully matching, plus 339 partially matching documents found.

Latest Intelligence

  • The Golden Goose The Golden Goose

    Biosimilar fail. Another stumbling block has been our over-reliance on market-based solutions to this problem, ie, generics. ... The thinking was at that time we’d solved the biosimilar problem, and here we are nine years later saying, no, we haven’t.

  • Transitions in healthcare Transitions in healthcare

    Switching from an originator biologic to a cheaper biosimilar. These are all examples of the kind of treatment transitions patients experience that can be supported by Patient Support Programmes.

  • It’s not the end of the world, is it? It’s not the end of the world, is it?

    Whether we market branded products that offer no real superiority over generics, biosimilars or me-toos or we sell innovative products whose price differential is not financially justified, much of what

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    It will compete with numerous treatment modalities, including entrenched biological agents and biosimilar biologicals.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The world’s biggest selling drug, Humira, lost its market exclusivity in Europe to biosimilar competition in 2018, and AbbVie is well aware of the impending US patent expiry in 2022. ... Finally, 2019 will see a rapid increase in the uptake of Humira

More from intelligence
Approximately 11 fully matching, plus 57 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest from PMHub

  • The 'winner takes all' pricing game

    Conclusions. Pharmaceutical tendering will stay as a key procurement approach for pharmaceutical products, especially for hospital products but also in outpatient settings for generics/biosimilars or other segments of products with

  • Launch Excellence 2020

    In the past year, the competition in biosimilars and complex generics has complicated the launch landscape.

  • How ready are you for launch?

    Specifically, it has focused its efforts on increasing competition in biosimilars and complex generics, which are difficult to copy, in a bid to increase competition and drive down prices.

  • Three strategies for managing loss of exclusivity successfully

    In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. Eli Lilly responded by launching an LOE strategy that tapped into patients’ desire for a stable treatment plan.

  • Webcast: Navigating new frontiers: Ways to find space in the future RA market

    in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... Uptake curve of JAKS compared to other new entrants and biosimilars.

More from PMHub
Approximately 13 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...